Nautilus Biotechnology, Inc. · NASDAQ:NAUT
Nautilus Biotechnology — SPAC Merger (February 2021)
45 slides from Nautilus Biotechnology's SPAC merger presentation, Feb 8, 2021
Slide 1: Delivering on the Promise of the Human Proteome
Delivering on the Promise of the Human Proteome Nautilus Biotechnology Confidential – Do Not Distribute FEBRUARY 2021
Slide 2: Disclaimer
Disclaimer 2 This presentation (“Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to the proposed business combination between ARYA Sciences Acquisition Corp III (“ARYA”) and Nautilus Biotechnolo
Slide 3: Our Opportunity: To Revolutionize Biomedicine
The proteome is among the most dynamic and valuable sources of biological insight.But current technologies lack the sensitivity, throughput, and ease of use required to address the needs of the biomedical community. Our Opportunity: To Revolutionize Biomedicine A fundamentally new approach is requir
Slide 4: Comprehensive proteomics analysis reimagined
Nautilus Biotechnology Confidential – Do Not Distribute 4 Comprehensive proteomics analysis reimagined Single molecule proteomics platform with integrated machine learning designed to enable unprecedented sensitivity and scale $25+ Billion opportunity across proteomics and adjacent markets First pha
Slide 5: Nautilus' Revolutionary Innovation Was Not Possible Until Now
Nautilus’ Revolutionary Innovation Was Not Possible Until NowRequired counter-intuitive science and the maturation of key disciplines Nautilus has innovated strengths in each discipline and then leveraged these strengths across those disciplines to achieve something designed to be revolutionary Foun
Slide 6: Current Proteomics Ecosystem
Current Proteomics Ecosystem Nautilus Biotechnology Confidential – Do Not Distribute 6 Sample Collection BiopsyResectionBiofluid (Blood, CSF, Saliva)Laser-capture microdissectionCell sorting (FACS)Primary cell cultureStable cell line cultureXenograft Sample Extraction Chemical LysisGradient centrifu
Slide 7: Current Methods Can't See Valuable Biology
Nautilus Biotechnology Confidential – Do Not Distribute 7 Mass Spec Solutions today only capture a fraction of the proteome from Blood or Cells There is No solution today to measure and quantify intact proteoforms Current Methods Can’t See Valuable Biology
Slide 8: We set out to re-invent proteomics from the ground up
8 We set out to re-invent proteomics from the ground up Setting Ambitious Goals: To Read and Quantify the Proteome and Proteoforms Nautilus Biotechnology Confidential – Do Not Distribute Easy to Use It Ultra-Sensitive Reproducible and Robust Rapid Run Time Integrated Complete Any Lab Can Run It Sing
Slide 9: Integration of Breakthrough Innovations Across the Platform
Integration of Breakthrough Innovations Across the PlatformDesigned to Allow Nautilus to Access Full Resolution Digital Proteomic Data 9 Sample Preparation& Deposition Instrumentation and Reagents for Single-Molecule Measurement Machine Learning-Based Analysis Digital Proteomic Data Protein Decoding
Slide 10: Simple, Rapid, and Robust Sample Preparation
Simple, Rapid, and Robust Sample Preparation 10 Nautilus Biotechnology Confidential – Do Not Distribute Step 1 Blood or Cells or Step 4 Protein-Scaffold Conjugation Step 5 Protein-Scaffold Library for Deposition Step 3 Protein Labeling Key Takeaways: Rapid and Effective Chemistry Step 2 Protein Extr
Slide 11: Hyper-Dense Single Molecule Microarray Enables Deep, Sensitive Profiling
Hyper-Dense Single Molecule Microarray Enables Deep, Sensitive Profiling 11 Nautilus Biotechnology Confidential – Do Not Distribute 1010 landing pads/Chip Sensitively measure down to 1 molecule in 1000 cellsExtreme sensitivity and wide dynamic range 106105104103102 10-1 101 103 105 Key Takeaways: 30
Slide 12: High Resolution Multi-Cycle Imaging of Affinity Reagents
High Resolution Multi-Cycle Imaging of Affinity Reagents Nautilus Biotechnology Confidential – Do Not Distribute 12 Integrated fluidics and imaging on instrumentDesigned to sensitively measure tens-of-billions of molecules across hundreds of cycles in approximately a day6 sample multiplexing, with p
Slide 13: Image Analysis Creates Digital Proteomic Data
Image Analysis Creates Digital Proteomic Data > > > > > Nautilus Biotechnology Confidential – Do Not Distribute Algorithmic processing & machine learning Data Compressed into Coordinate Binding Matrix Coordinate1,11,22,1 2,23,13,2 Binding sequence1,0,0…0,0,1…0,1,1…1,0,0…1,0,1…0,0,0… Image & data red
Slide 14: Machine Learning Analytics in Cloud to Decode the Proteome
Machine Learning Analytics in Cloud to Decode the Proteome Nautilus Biotechnology Confidential – Do Not Distribute > > > > > Coordinate Binding Matrix Coordinate1,11,22,1 2,23,13,2 Binding sequence1,0,0…0,0,1…0,1,1…1,0,0…1,0,1…0,0,0… 14 Coordinate1,11,22,1 2,23,13,2 IDENTITYEGFRTP53cMETPTENBRAFMEK S
Slide 15: The Nautilus Platform is Highly Robust
The Nautilus Platform is Highly Robust Nautilus Biotechnology Confidential – Do Not Distribute 15 Negligible loss of detection ability Negligible Protein Loss First Cycle Last Cycle
Slide 16: Unlocking the Human Proteome: Protein Decoding Using Multi-Affinity Probe Reagents
Unlocking the Human ProteomeProtein Decoding Using Multi-Affinity Probe Reagents Nautilus Biotechnology Confidential – Do Not Distribute 16
Slide 17: Capable of Comprehensive Decoding of the Human Proteome
Capable of Comprehensive Decoding of the Human Proteome300 Cycle Multi-Affinity Probe Reagent System Run1 Nautilus Biotechnology Confidential – Do Not Distribute 17 Capable of Achieving >95% ProteomeCoverage 1Estimates based Nautilus computational analysis projecting the number of Nautilus designed
Slide 18: Unlocking the Mystery of Proteoforms
Unlocking the Mystery of Proteoforms Nautilus Biotechnology Confidential – Do Not Distribute 18 DNA Protein Isoforms 1International Journal of Analytical Chemistry. 2016; 2016: 7436849. The Size of the Human Proteome: The Width and Depth, Elena A. Ponomarenko et al. The pattern of post-translational
Slide 19: Proteoform Quantification: A Novel 2021 Technology Application
Proteoform Quantification A Novel 2021 Technology Application Which drugs work and to what extent is defined not by just the total amount of PTMs and splice forms, but instead by how combinations of specific alterations operate together. Creating a technology to see these PTM patterns, and measure t
Slide 20: Single Molecule Proteoform Detection Preserves Biological Information
Single Molecule Proteoform Detection Preserves Biological Information Nautilus Biotechnology Confidential – Do Not Distribute 20 > > > > > Key Takeaways: Sensitively quantify proteoform molecular heterogeneityOpen platform to apply virtually any high specificity reagent Cycle 1 Cycle 3 Cycle 5
Slide 21: Open Platform Technology Compatible with Many Affinity Reagent Options
Open Platform Technology Designed to be Compatible with Many Affinity Reagent Options 1BCC Research. Global Markets for Research Antibodies (2018).Nautilus Biotechnology Confidential – Do Not Distribute 21 Multi-affinity Aptamer Engineered Mini-protein Binder Designed to be Compatible withoff-the-sh
Slide 22: Long-Term Transformation of Healthcare by Proteomics
Long-Term Transformation of Healthcare by Proteomics AI Powered Drug Discovery Clinical Diagnostics Precision & Personalized Medicine + Growth and Market Expansion Opportunity Large Market Opportunity Ready for Disruption Source: Allied Market Research: Proteomics Market Global Opportunity Analysis
Slide 23: Potential Markets & Applications
Potential Markets & Applications Nautilus Biotechnology Confidential – Do Not Distribute 23 Multi-Omics & Systems Biology Proteoform Composition & Landscape Proteome Profiling (species agnostic) Biomarker & Drug Target Discovery Mechanism of Action Studies Toxicity Profiling and Prediction Longitudi
Slide 24: Significant Target Milestones on Path to Comprehensive Proteomic Profiling
Significant Target Milestones on Path to Comprehensive Proteomic ProfilingEach Step Represents a Potentially New and Unprecedented Advancement Nautilus Biotechnology Confidential – Do Not Distribute 24 LATE 2021 EARLY 2022 LATE 2022 MID OF 2023 LATE OF 2023 DATA PRODUCTION AT NAUTILUS CUSTOMER GENER
Slide 25: Planned Three Phase Commercial Strategy
Planned Three Phase Commercial Strategy 25 Application Development Instrument Pre-Sales 1 2 Nautilus Biotechnology Confidential – Do Not Distribute Partnerships & CollaborationsJointly publish dataMultiple high potential discovery and IP license optionsPharma validation and endorsement pre-commercia
Slide 26: Planned Sales Model and Key Customer Segments
Nautilus Biotechnology Confidential – Do Not Distribute Planned Sales Model and Key Customer Segments Target Customers Land and Expand Sales Model 26 Pharmaceutical & Biotech B2B Diagnostic Service Partnerships Academic & Research Community Large-Scale Omics Core Laboratories Contract Research Organ
Slide 27: Each Milestone Expected to Create New Opportunities to Partner
2,500 Proteins/run Single MoleculeMulti-Cycle Read Out 10,000 Proteins/run Comprehensive Proteome Instrument Launch & Scale Up DATA PRODUCTION AT NAUTILUS CUSTOMER GENERATED DATA Each Milestone Expected to Create New Opportunities to PartnerEvery Step Represents a Potentially New and Unprecedented A
Slide 28: Establish Collaborations & Partnerships
2,500 Proteins/run Single MoleculeMulti-Cycle Read Out 10,000 Proteins/run Comprehensive Proteome Instrument Launch & Scale Up DATA PRODUCTION AT NAUTILUS CUSTOMER GENERATED DATA Nautilus Biotechnology Confidential – Do Not Distribute 28 Establish Collaborations & PartnershipsEngage early, create va
Slide 29: Early Access & POC Engagements
2,500 Proteins/run Single MoleculeMulti-Cycle Read Out 10,000 Proteins/run Comprehensive Proteome Instrument Launch & Scale Up DATA PRODUCTION AT NAUTILUS CUSTOMER GENERATED DATA Nautilus Biotechnology Confidential – Do Not Distribute 29 TARGET: Advanced Proteomic Laboratories STRATEGY:Seed Market f
Slide 30: Instrument & Consumables
2,500 Proteins/run Single MoleculeMulti-Cycle Read Out 10,000 Proteins/run Comprehensive Proteome Instrument Launch & Scale Up DATA PRODUCTION AT NAUTILUS CUSTOMER GENERATED DATA Nautilus Biotechnology Confidential – Do Not Distribute 30 Instrument & Consumables TARGET: Create Diverse Initial Custom
Slide 31: Planned Strategic Elements of the Platform Designed to Create Competitive Advantage
Planned Strategic Elements of the Platform Designed to Create Competitive Advantage in the Field Nautilus Biotechnology Confidential – Do Not Distribute 31 First to Market with Novel Detection Platform Highly Disruptive Technology Immense Data Production Capacity Proven Commercial Model Diversified
Slide 32: Nautilus and Genentech Collaboration
Nautilus and Genentech Collaboration Nautilus Biotechnology Confidential – Do Not Distribute Signed a pilot study Research Collaboration Agreement in December 2020.We are collaborating with Genentech using the Nautilus system to analyze and map the proteoform landscape of a Genentech protein target
Slide 33: Patent Portfolio Summary
Patent Portfolio Summary(as of January 21, 2021) Nautilus Biotechnology Confidential – Do Not Distribute 33 SAMPLE PREPARATION1 Patent Family SINGLE MOLECULE MICROARRAY2 Patent Families PROBES & IMAGING5 Patent Families MACHINE LEARNING & ANALYTICS2 Patent Families IMAGE ANALYSIS1 Patent Family Over
Slide 34: Leadership
Leadership 34 Sujal PatelFounder & CEO Anna MowryCFO Parag MallickFounder & CSO Nick NelsonSVP, CBO Investors Scientific Advisory Board Ruedi Aebersold, PhDProf. Systems Biology,Institute of Molecular Systems Biology in ETH Zurich (IMSB) Lee Hartwell, PhDPresident and Director Emeritus, Fred Hutchin
Slide 35: Long Term Financial Targets
Nautilus Biotechnology Confidential – Do Not Distribute 35 Target Range as % of Revenue GROSS MARGIN 70% R&D OpEx 15-20% SG&A OpEx 20-25% OPERATING INCOME 25-30% Long Term Financial Targets
Slide 36: Why Nautilus?
Nautilus Biotechnology Confidential – Do Not Distribute WhyNautilus? We believe that humanity needs a dramatic acceleration of drug development and that a bold scientific leap is required to make possible a new world of precision and personalized medicine. To deliver, we need to radically reinvent p
Slide 37: Merging with ARYA III Provides a Direct Path to IPO
37 Merging with ARYA III Provides us with a direct path to IPO and greater access to capitalEnables us to go public in one step vs. the typical two or three step venture backed private rounds, and provides access to a strong market backdrop today to properly fund and grow our businessProvides us an
Slide 38: Terms of Transaction
38 Terms of Transaction Nautilus Biotechnology Confidential – Do Not Distribute Pro Forma Valuation Sources of Funds (1) Uses of Funds (1) Pro Forma Shares Outstanding 129,187 Implied Share Price $ 10.00 PF Equity Value $ 1,291,865 Less: PF Cash $ (386,500) Implied PF Enterprise Value $ 905,365 Equi
Slide 39: Thank You
Thank You Nautilus Biotechnology Confidential – Do Not Distribute
Slide 40: Appendix
Appendix Nautilus Biotechnology Confidential – Do Not Distribute
Slide 41: Balance Sheet
41 Balance Sheet Nautilus Biotechnology Confidential – Do Not Distribute Note: Financial data above are unaudited and subject to change based upon completion of a PCAOB audit for the fiscal year ended December 31, 2019. Cash, cash equivalents, and short-term investments total $76.7M as of December 3
Slide 42: Statement of Operations
42 Statement of Operations Nautilus Biotechnology Confidential – Do Not Distribute Note: Financial data above are unaudited and subject to change based upon completion of a PCAOB audit for the fiscal year ended December 31, 2019. The preliminary financial data included herein has been prepared by, a
Slide 43: Statement of Cash Flows
43 Statement of Cash Flows Nautilus Biotechnology Confidential – Do Not Distribute Note: Financial data above are unaudited and subject to change based upon completion of a PCAOB audit for the fiscal year ended December 31, 2019. The preliminary financial data included herein has been prepared by, a
Slide 44: Nautilus' Projected Financial Information
Nautilus Biotechnology Confidential – Do Not Distribute 44 Year ending December 31, ($ in millions) 2021 2022 2023 2024 2025 Total Revenue $0 $4 $17 $77 $183 Gross Profit $0 $1 $9 $49 $127 EBITDA(3) ($46) ($72) ($84) ($73) ($42) Nautilus’ Projected Financial Information(1), (2) Notes:(1) The financi
Slide 45: Summary Risk Factors
Summary Risk Factors 1 Risks Associated with Nautilus’ BusinessNautilus’ business is subject to numerous risks and uncertainties that you should consider before investing. The summary risks and uncertainties described below are not the only ones Nautilus faces. Additional risks and uncertainties not